An Overview of HIV and AIDS; Current and Future Treatment Options
DOI:
https://doi.org/10.58445/rars.2065Keywords:
HIV, AIDS, gene therapyAbstract
HIV is a disease that is communicable through bodily fluids such as blood or sweat. It is highly infectious and doesn't have a viable cure. There are currently several treatment options known as antiretroviral therapies (ART's), that stall the replication and spread of HIV within the human body. However these therapies are not permanent and are not cost effective. This had led to research within the field of Human gene editing, to see if HIV can be permanently cured all at once within a person. The results of this review paper show that gene editing could be a viable and promising cure going forwards, where that technology is available. However gene editing is expensive and not as accsesible as ART's. However gene editing has already been approved for use in countries, like the United States for treatment of other diseases, like sickle cell, proving to be a promising avenue in the field of HIV treatment and prevention.
References
-1. Ayala, George, and Andrew Spieldenner. “HIV Is a Story First Written on the Bodies of Gay and Bisexual Men.” American journal of public health vol. 111,7 (2021): 1240-1242. doi:10.2105/AJPH.2021.306348
-2. “Capsid Inhibitor(S) | NIH.” Clinicalinfo.hiv.gov, clinicalinfo.hiv.gov/en/glossary/capsid-inhibitors.
-3.Carrington, M., et al. “Novel Alleles of the Chemokine-Receptor Gene CCR5.” American Journal of Human Genetics, vol. 61, no. 6, Dec. 1997, pp. 1261–67, https://doi.org/10.1086/301645. Accessed 17 May 2021.
-4.“CCR5 Antagonist | NIH.” Clinicalinfo.hiv.gov, clinicalinfo.hiv.gov/en/glossary/ccr5-antagonist.
CDC. “HIV Cost-Effectiveness.” CDC, 2019, www.cdc.gov/hiv/programresources/guidance/costeffectiveness/index.html.
-5.---. “How HIV Spreads.” HIV, 14 May 2024, www.cdc.gov/hiv/causes/index.html.
-6.---. “The AIDS Epidemic in the United States, 1981-Early 1990s | David J. Sencer CDC Museum |
CDC.” Www.cdc.gov, CDC, 26 Mar. 2021, www.cdc.gov/museum/online/story-of-cdc/aids/index.html.
-7. Cohen, Jon. “How Did the ‘Berlin Patient’ Rid Himself of HIV?” Www.science.org, 25 Sept. 2014, www.science.org/content/article/how-did-berlin-patient-rid-himself-hiv.
-8. Dash, Prasanta K et al. “CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice.” Proceedings of the National Academy of Sciences of the United States of America vol. 120,19 (2023): e2217887120. doi:10.1073/pnas.2217887120
-9. Florez, Chase V. “Zidovudine or Azidothymidine (AZT) | the Embryo Project Encyclopedia.” Embryo.asu.edu, 30 June 2020, embryo.asu.edu/pages/zidovudine-or-azidothymidine-azt.
-10. Freitas, Martiela Vaz de et al. “Protection is not always a good thing: The immune system's impact on gene therapy.” Genetics and molecular biology vol. 45,3 Suppl 1 e20220046. 15 Jul. 2022, doi:10.1590/1678-4685-GMB-2022-0046
-11. Ganguly, Prabarna. “Retrovirus.” Genome.gov, 2019, www.genome.gov/genetics--glossary/Retrovirus.
-12. Gibas, Kevin M et al. “Two-drug regimens for HIV treatment.” The lancet. HIV vol. 9,12 (2022): e868-e883. doi:10.1016/S2352-3018(22)00249-1
-13. “Guide RNA (GRNA).” Innovative Genomics Institute (IGI),
innovativegenomics.org/glossary/guide-rna/.
-14. HIV.gov. “A Timeline of HIV and AIDS.” HIV.gov, U.S. Department of Health & Human Services, 2022, www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline.
-15. Hütter, Gero, et al. “Long-Term Control of HIV ByCCR5Delta32/Delta32 Stem-Cell Transplantation.” New England Journal of Medicine, vol. 360, no. 7, Feb. 2009, pp. 692–98, https://doi.org/10.1056/nejmoa0802905.
-16. Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role in HIV infection and treatment. JAMA. 2006 Aug 16;296(7):815-26. doi: 10.1001/jama.296.7.815. PMID: 16905787.
-17. Mancuso, Pietro et al. “CRISPR based editing of SIV proviral DNA in ART treated non-human primates.” Nature communications vol. 11,1 6065. 27 Nov. 2020, doi:10.1038/s41467-020-19821-7
-18. Modrzejewski, Dominik et al. “Which Factors Affect the Occurrence of Off-Target Effects Caused by the Use of CRISPR/Cas: A Systematic Review in Plants.” Frontiers in plant science vol. 11 574959. 23 Nov. 2020, doi:10.3389/fpls.2020.574959
-19. National Cancer Institute. “Https://Www.cancer.gov/Publications/Dictionaries/Cancer-Terms/Def/Allogeneic-Stem-Cell-Transplant.”
-20. Www.cancer.gov, 2 Feb. 2011, www.cancer.gov/publications/dictionaries/cancer-terms/def/allogeneic-stem-cell-transplant
-21. National Center for Biotechnology Information. "PubChem Compound Summary for CID 5789, Thymidine" PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Thymidine
Accessed 29 November, 2024.
-22. National Research Council (US) Panel on Monitoring the Social Impact of the AIDS Epidemic. “The Social Impact of AIDS in the United States.” PubMed, edited by Albert R. Jonsen and Jeff Stryker, National Academies Press (US), 1993, www.ncbi.nlm.nih.gov/books/NBK234570/.
-23. NIH.
“FDA-Approved HIV Medicines.” Hivinfo.nih.gov, 8 Feb. 2021, hivinfo.nih.gov/understanding-hiv/fact-sheets/fda-approved-hiv-medicines.
-24. “Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) | ClinicalInfo.” Clinicalinfo.hiv.gov clinicalinfo.hiv.gov/en/glossary/non-nucleoside-reverse-transcriptase-inhibitor-nnrti.
-25. Onyema Ogbuagu, et al. Efficacy and Safety of the Novel Capsid Inhibitor Lenacapavir to Treat Multidrug-Resistant HIV: Week 52 Results of a Phase 2/3 Trial. July 2023, https://doi.org/10.1016/s2352-3018(23)00113-3. Accessed 17 July 2023.
-26. Paik, Julia. “Lenacapavir: First Approval.” Drugs, vol. 82, no. 14, Sept. 2022, pp. 1499–504, https://doi.org/10.1007/s40265-022-01786-0.
-27. Perez, Elena E et al. “Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases.” Nature biotechnology vol. 26,7 (2008): 808-16. doi:10.1038/nbt1410
-28. Peters, Ellen, and and Collins Iwuji. “Efficacy, Safety and Tolerability of Biktarvy in HIV-1 Infection: A Scoping Review.” Antiviral Therapy, vol. 28, no. 1, Feb. 2023, p. 135965352311590, https://doi.org/10.1177/13596535231159030.
-29. “Planned Parenthood.” Plannedparenthood.org, 2020, www.plannedparenthood.org/get-care/our-services/hiv-services.
-30. “Protease Inhibitor (PI) | NIH.” Clinicalinfo.hiv.gov, clinicalinfo.hiv.gov/en/glossary/protease-inhibitor-pi.
-40. PubChem. “Thymidine.” Pubchem.ncbi.nlm.nih.gov, pubchem.ncbi.nlm.nih.gov/compound/Thymidine.
-41. Redman, Melody et al. “What is CRISPR/Cas9?.” Archives of disease in childhood. Education and practice edition vol. 101,4 (2016): 213-5. doi:10.1136/archdischild-2016-310459
-42. Research, Center for Biologics Evaluation and. “CASGEVY.” FDA, Dec. 2023, www.fda.gov/vaccines-blood-biologics/casgevy.
-43. “Reverse Transcriptase (RT) | NIH.” Clinicalinfo.hiv.gov, clinicalinfo.hiv.gov/en/glossary/reverse-transcriptase-rt.
-44. Segal-Maurer, Sorana, et al. “Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.” New England Journal of Medicine, vol. 386, no. 19, May 2022, pp. 1793–803, https://doi.org/10.1056/nejmoa2115542.
-45. “SUNLENCA® (Lenacapavir) Dosing and Administration | HCP Site.” Www.sunlencahcp.com, www.sunlencahcp.com/dosing-and-administration/sunlenca-dosing/.
-46. “The History of FDA’s Role in Preventing the Spread of HIV/AIDS.” FDA, Mar. 2021, www.fda.gov/about-fda/fda-history-exhibits/history-fdas-role-preventing-spread-hivaids.
-47. Torian, Lucia, et al. “HIV Surveillance --- United States, 1981--2008.” Www.cdc.gov, 3 June 2011, www.cdc.gov/mmwr/preview/mmwrhtml/mm6021a2.htm.
-48. What Are CD4 Cells? www.cdc.gov/hiv/pdf/effective-interventions/treat/steps-to-care/my-stc/cdc-hiv-stc-what-are-cd4-cells.pdf.
-49. “What to Start: Choosing an HIV Treatment Regimen | NIH.” Hivinfo.nih.gov, 16 Aug. 2021, hivinfo.nih.gov/understanding-hiv/fact-sheets/what-start-choosing-hiv-treatment-regimen.
-50. Wilen, C. B., et al. “HIV: Cell Binding and Entry.” Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 8, Apr. 2012, pp. a006866–66, https://doi.org/10.1101/cshperspect.a006866.
Downloads
Posted
Categories
License
Copyright (c) 2024 Rithika Nandivada
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.